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adjusted 70 and CPI-H adjusted 40) and for basic refund
category 147 (61; 35), respectively. In 1990 = 100 index
the respective ﬁgures were: all drugs 110 (88; 68), pre-
scription based 105 (83; 64), reimbursed 102 (81; 62),
Basic Refund (“50%”) 102 (81; 62), Lower Special
Refund (“75%”) 102 (81; 62) and Higher Special Refund
(“100%”) 103 (82; 63). CONCLUSIONS: Nominal drug
wholesale prices have increased in Finland since 1980 and
also slightly from 1990, but real prices have constantly
decreased. Depending from the adjustment index used,
the real prices of all drugs have decreased from 30–60%
since 1980, or 12–33% since 1990. For reimbursed drugs
the development was similar. The prices in general, and
in the Basic Refund category have decreased 19–38%
since 1990, and even 40–75% since 1980. Since the effec-
tiveness of drugs has not decreased during the time period
studied, we suggest that the drug treatment has clearly
become more cost-effective in Finland.
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COMPARISON OF MARKET EXCLUSIVITY OF
PHARMACEUTICALS IN CANADA, THE UNITED
STATES, THE UNITED KINGDOM AND FRANCE
Palmer WN, Neale S, Salazar A
Palmer D’Angelo Consulting Inc, Ottawa, ON, Canada
OBJECTIVES: To compare the periods of market 
exclusivity for branded pharmaceuticals in Canada with
the United States, the United Kingdom, and France.
METHODS: We identiﬁed the 50 top selling generic mol-
ecules in Canada. The dates of ﬁrst sale of the original
brand and corresponding ﬁrst generic for each molecule
were compared to determine the period of market exclu-
sivity of each branded product. Corresponding data were
collected and periods of exclusivity calculated for the US,
UK and France. In cases where a generic had yet to be
introduced in a comparator country, the period of market
exclusivity was calculated as of May 2003. Average
market exclusivity for the products in the study was cal-
culated for each country. RESULTS: The average period
of market exclusivity for the 50 brands in Canada was
10.7 years, considerably lower than in the other countries
(US 12.1; UK 15.0; France 19.1 years). There was incom-
plete international information for nine of the ﬁfty mol-
ecules. When the analysis was restricted to the remaining
41 products the results were similar (Canada 9.8; US
12.0; UK 15.0; France 17.0 years). Although the sample
products represent the 50 top selling generic molecules in
Canada, many were not yet marketed as generics in the
comparator countries (US 6; UK 11; France 21). CON-
CLUSIONS: The analysis indicates that on average,
market exclusivity for the same brands in Canada was
signiﬁcantly shorter than in the US, UK and France. A
more favourable regulatory climate for generic drugs in
Canada (early working, faster generic approval times,
mandatory generic substitution laws etc.) and longer
approval times for brand drugs may account for some 
of the differences. Despite changes in patent legislation
(1987, 1993) to restore patent protection, the analysis
does not suggest a trend toward longer periods of market
exclusivity for newer brands in Canada.
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TO 2000
Gaspar M, Modamio P, Lastra C, Mariño E
University of Barcelona, Barcelona, Spain
OBJECTIVES: When the selection of treatments ﬁnanced
by public money is considered, rational decisions to incor-
porate a new drug in clinical practice has to be even more
exact. Here, we analyse the incorporation of new medi-
cines ﬁnanced by the Spanish National Health Service
(NHS) into the clinical practice from 1996 to 2000. The
Spanish NHS covers more than 95% of the population.
METHODS: A retrospective study has been made, select-
ing new medicines classiﬁed following the degree of ther-
apeutic innovation at the moment of authorisation (A*,
A, B, C, and D), according to the criterion of the Min-
istry of Health and Consume (MHC). Consume data were
provided by the MHC database. They were expressed as
Price for Sale Direct to Customer, tax-free (PVP) by means
of Millions of Pesetas (MPTA) and in number of con-
sumed units. The rapid incorporation of new medicines
into the clinical practice (the one-hundred tops) and the
evolution of their consume were the indicators used.
RESULTS: The total number of new drugs selected was
68 (19, 20, 19, 8, and 2 in the years 96, 97, 98, 99, and
00, respectively). None of them were categorised in type
A*. Mostly were types B (29.4%) and C (67.6%). From
those, Olanzapine (96), Atorvastatin (97), Cerivastatine
(98), Clopidogrel (99), or Celecoxib (00), among others,
had a very fast incorporation. Analysing the evolution of
new drug consumption, it detected that some of them
have been withdrawn from the clinical practice because
of adverse drug events (Ebrotidine (96) in 1998,
Grepaﬂoxacin (98) in 1999 or Cerivastatine (98) in
2001). CONCLUSIONS: The indicators used in this
study have permitted analyse the quality of the selection
of treatments ﬁnanced by public money. From the results
obtained, it would strongly recommend an urgent revi-
sion of type C (67.6%) new drugs ﬁnanced by NHS.
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SURVEY ON DRUG VALUE ASSESSMENT
AMONG PRESCRIBERS AND PAYERS IN ITALIAN
HOSPITALS
Negrini C, D’Ausilio A, Lopatriello S, Berto P
pbe consulting,Verona, Italy
OBJECTIVES: To identify and analyse elements on which
hospital decision makers base their therapy value assess-
ment, both in general terms and in relation to acute Heart
Failure (aHF)treatment. METHODS: Thirty face to face
interviews (15 hospital pharmacists and 15 cardiologists)
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were conducted in December 2002 in 15 Italian hospitals.
Three major topics were investigated, Hospital Formulary
(HF) listing process, epidemiology and medical need in
aHF, HF listing process for aHF drugs, a semi-structured
questionnaire was used and both spontaneous and
elicited citations were recorded. RESULTS: Most quoted
requisites were: superior efﬁcacy in comparison to avail-
able alternatives, better cost-effectiveness proﬁle, credi-
bility, and size of clinical studies. Innovation is relevant
to pharmacists, while QoL and length of hospital stay are
important mostly for cardiologists. Cardiologist and
pharmacists showed different level of information regard-
ing aHF. Similar average yearly number of aHF hospital-
isation were reported by both targets (cardiologists =
968,7 range 1–1000; pharmacists = 937,5 range 250–
1500) but response rate was only 27% among pharma-
cists. Eighty-seven percent of the pharmacists were unable
to rate aHF mortality in their hospitals, estimated by 
cardiologists from 6–7% to 60–70%. Cardiologists
scored clinical efﬁcacy (93%) and absence of contra-
indication/interactions (60%) as the most important char-
acteristics of aHF products, while innovation and clinical
documentation size and credibility (40% and 47%
respectively) are important to pharmacists. Drug price
may negatively inﬂuence drug listing, limiting the adop-
tion of new products. Reimbursement level assigned by
the Ministry of Health is considered an indicator of drug
beneﬁt evidence. CONCLUSIONS: Drug efﬁcacy is still
guiding product assessment process but cost-effectiveness
information is progressively gaining relevance. Decision
makers information on disease epidemiology and medical
need may be reinforced, allowing for better acceptance of
new effective product. Global treatment cost might be
considered in drug assessment instead of product price in
order to motivate manufacturers in producing robust and
credible economic information.
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REIMBURSING OFFICE-BASED DRUG
MANAGEMENT COSTS: POLICY OPTIONS
Baker JJ
Resource Group, Ltd, Pickton,TX, USA
OBJECTIVE: The Centers for Medicare and Medicaid
Services (CMS) computes clinical staff incident-to services
in physician ofﬁces under a zero work hour alternative
method. This study compares the results of CMS alter-
native method payment computations for indirect over-
head costs with the actual resource-based level of effort
for ofﬁce-based drug management costs as incurred 
in U.S. physicians’ ofﬁces. METHODS: Phase I: CMS
methods used for zero work hour practice expense rate-
setting were identiﬁed. Underlying assumptions were
examined and formal methodology evaluations were col-
lected. Phase II: On-site activity analyses were performed
in over 70 physicians’ ofﬁces located in 27 states. An
activity database was created from study data obtained
through direct observation and on-site interviews. Analy-
ses employing descriptive statistics identiﬁed activities,
tasks, and staff type involved in speciﬁc tasks, including
drug management. The activity analysis ﬁndings were
compared to the CMS reimbursement assumptions about
these activities. RESULTS: A database of CMS method-
ology explanations, visuals, and evaluations was created.
Activity analysis identiﬁed costs of labor and space to
order, track, receive, store and pay for the drug; drug
inventory carrying costs; net receivables carrying costs
and average bad debt cost. Study analyses illustrate that
current CMS practice expense payments do not ade-
quately recognize drug management costs in physicians’
ofﬁces. Study results revealed a statistically signiﬁcant dif-
ferential between actual and assumed use of administra-
tive labor for indirect overhead zero work pool tasks,
including those of drug management. CONCLUSIONS:
CMS zero work hour methodology to compute payments
for ofﬁce-based practice expense is deﬁcient as to drug
management costs. Payment for this component does not
align with actual practice occurring within the physicians’
ofﬁces. These ﬁndings will be of use to economists, cost
accountants, and policy makers interested in arriving 
at an equitable resource-based payment for drug 
management.
PHP19
CONSUMER VALUATION OF PRESCRIPTION
DRUG BENEFIT PLANS
Taylor SD1, McKercher PL1, Gagnon JP2
1University of Michigan, Ann Arbor, MI, USA; 2Aventis
Pharmaceuticals Inc, Bridgewater, NJ, USA
OBJECTIVE: To examine consumers’ perspective of the
quality of prescription drug beneﬁt plans (Rx plan) using
a prescription-drug quality index. Additionally, con-
sumers’ satisfaction and perception of importance of Rx
plans were evaluated. METHODS: Consumers with pre-
scription drug beneﬁts were recruited from community
pharmacies and random-digit dialing (RDD) to partici-
pate in a telephone survey. The questionnaire was con-
structed from published literature and in-depth interviews
with six pharmacists, four consumers, and two employee
beneﬁt managers. RESULTS: Two hundred and one con-
sumers participated in a 20-minute telephone interview.
When asked to select optional health services over and
above hospital and medical services, 62.6% selected pre-
scription drugs services as most important. Using a 10-
point scale, with 10 as the highest score, the average
perceived quality rating of prescription drug beneﬁt plans
was 7.91 (2.0); the average rating for satisfaction with
the plan was 7.22 (2.3); and the average rating for impor-
tance of the plan was 9.15 (1.3). Few consumers (20%)
reported having plan-related problems when obtaining
prescription medications. The majority (87%) reported
having a copayment/coinsurance. The average prescrip-
tion drugs out-of-pocket payment was $560 (ranging
from $0–$7200) and the median was $200. Of the six
prescription-drug quality indicators, only two were found
